Plasma activity of thrombin activatable fibrinolysis inhibitor in Crimean-Congo hemorrhagic fever

Journal of Infection

Volumn 55, Issue 2, 2007, Pages 184-187

  Sonmez, Mehmet ^a   Aydin, Kemalettin ^a   Durmus, Ahmet ^a   Sucu, Nurgul ^a   Yilmaz, Mustafa ^a   Akdogan, Elif ^a   Koksal, Iftihar ^a   Ovali, Ercument ^a   Omay, Serdar Bedii ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Crimean Congo hemorrhagic fever; Thrombin activatable fibrinolysis inhibitor

Indexed keywords

C REACTIVE PROTEIN; IMMUNOGLOBULIN M; SERUM ALBUMIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADOLESCENT; ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BLEEDING; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SYNTHESIS; FATALITY; FEMALE; FIBRINOLYSIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER; LIVER DYSFUNCTION; MALE; PATHOGENESIS; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PROTHROMBIN TIME; SCHOOL CHILD; VIRUS HEMORRHAGIC FEVER; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; CARBOXYPEPTIDASE U; CASE-CONTROL STUDIES; CHILD; FEMALE; HEMORRHAGIC FEVER, CRIMEAN; HUMANS; INTERNATIONAL NORMALIZED RATIO; LIVER; MALE; MIDDLE AGED; PROTHROMBIN TIME;

EID: 34447104960     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2007.02.010     Document Type: Article

References (19)

1. Whitehouse C.A. Crimean-Congo hemorrhagic fever. Antiviral Res 64 (2004) 145-160
2. Ergonul O. Crimean-Congo haemorrhagic fever. Lancet Infect Dis 6 (2006) 203-214
3. Karti S.S., Odabasi Z., Korten V., Yilmaz M., Sonmez M., Caylan R., et al. Crimean-Congo hemorrhagic fever in Turkey. Emerg Infect Dis 10 (2004) 1379-1384
4. Swanepoel R., Gill D.E., Shepherd A.J., Leman P.A., Mynhardt J.H., and Harvey S. The clinical pathology of Crimean-Congo hemorrhagic fever. Rev Infect Dis 11 (1989) 794-800
5. Schwarz T.F., Nsanze H., and Ameen A.M. Clinical features of Crimean-Congo haemorrhagic fever in the United Arab Emirates. Infection 25 (1997) 364-367
6. Geisbert T.W., Young H.A., Jahrling P.B., Davis K.J., Larsen T., Kagan E., et al. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 163 (2003) 2371-2382
7. Bouma B.N., and Mosnier L.O. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis. Pathophysiol Haemost Thromb 33 (2003) 375-381
8. Bouma B.N., and Mosnier L.O. Thrombin activatable fibrinolysis inhibitor (TAFI) - how does thrombin regulate fibrinolysis?. Ann Med 38 (2006) 378-388
9. Nesheim M., and Bajzar L. The discovery of TAFI. J Thromb Haemost 3 (2005) 2139-2146
10. Bouma B.N., and Meijers J.C. New insights into factors affecting clot stability: a role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R). Semin Hematol 41 (2004) 13-19
11. Schnittler H.J., and Feldmann H. Viral hemorrhagic fever - a vascular disease?. Thromb Haemost 89 (2003) 967-972
12. Geisbert T.W., Hensley L.E., Gibb T.R., Steele K.E., Jaax N.K., and Jahrling P.B. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest 80 (2000) 171-186
13. Hensley L.E., Young H.A., Jahrling P.B., and Geisbert T.W. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett 80 (2002) 169-179
14. Geisbert T.W., Young H.A., Jahrling P.B., Davis K.J., Kagan E., and Hensley L.E. Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 188 (2003) 1618-1629
15. Shepherd A.J., Swanepoel R., and Leman P.A. Antibody response in Crimean-Congo hemorrhagic fever. Rev Infect Dis 11 (1989) 801-806
16. van Gorp E.C., Minnema M.C., Suharti C., Mairuhu A.T., Brandjes D.P., ten Cate H., et al. Activation of coagulation factor XI, without detectable contact activation in dengue haemorrhagic fever. Br J Haematol 113 (2001) 94-99
17. Zeerleder S., Schroeder V., Hack C.E., Kohler H.P., and Wuillemin W.A. TAFI and PAI-1 levels in human sepsis. Thromb Res 118 (2006) 205-212
18. Watanabe R., Wada H., Watanabe Y., Sakakura M., Nakasaki T., Mori Y., et al. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res 104 (2001) 1-6
19. Ergonul O., Celikbas A., Baykam N., Eren S., and Dokuzoguz B. Analysis of risk-factors among patients with Crimean-Congo haemorrhagic fever virus infection: severity criteria revisited. Clin Microbiol Infect 12 (2006) 551-554